500 related articles for article (PubMed ID: 35551661)
21. Immune checkpoint inhibitors in genitourinary malignancies.
Thana M; Wood L
Curr Oncol; 2020 Apr; 27(Suppl 2):S69-S77. PubMed ID: 32368176
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy in genitourinary malignancies.
Wattenberg MM; Fong L; Madan RA; Gulley JL
Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
[TBL] [Abstract][Full Text] [Related]
23. Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma.
Patel A; Bisno DI; Patel HV; Ghodoussipour S; Saraiya B; Mayer T; Singer EA
J Cancer Immunol (Wilmington); 2021; 3(2):115-136. PubMed ID: 34263255
[TBL] [Abstract][Full Text] [Related]
24. The promise of immunotherapy in genitourinary malignancies.
Zhang T; Armstrong AJ; George DJ; Huang J
Precis Clin Med; 2018 Dec; 1(3):97-101. PubMed ID: 30687563
[TBL] [Abstract][Full Text] [Related]
25. Current status and future perspectives of immunotherapy against urothelial and kidney cancer.
Kobayashi T; Takeuchi A; Nishiyama H; Eto M
Jpn J Clin Oncol; 2021 Oct; 51(10):1481-1492. PubMed ID: 34389866
[TBL] [Abstract][Full Text] [Related]
26. Current Role of Checkpoint Inhibitors in Urologic Cancers.
Attalla K; Sfakianos JP; Galsky MD
Cancer Treat Res; 2018; 175():241-258. PubMed ID: 30168125
[TBL] [Abstract][Full Text] [Related]
27. Immuno-Oncology Advances in Genitourinary Cancers.
Zang PD; Angeles A; Dorff TB; Pal SK; Gupta S
Am Soc Clin Oncol Educ Book; 2024 Jan; 44(2):e430428. PubMed ID: 38206274
[TBL] [Abstract][Full Text] [Related]
28. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the safety and immunological effects of Bacillus Calmette-Guérin in combination with checkpoint inhibitor therapy in a patient with neuroendocrine carcinoma: a case report.
Föhse K; Debisarun PA; Kilic G; van Dodewaard-de Jong JM; Netea MG
J Med Case Rep; 2023 Sep; 17(1):377. PubMed ID: 37661259
[TBL] [Abstract][Full Text] [Related]
30. [Immunotherapy for locally advanced or metastatic urothelial carcinoma: research advances and perspectives].
Ai K; Li Y
Zhonghua Wai Ke Za Zhi; 2021 Nov; 59(11):881-885. PubMed ID: 34743447
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Landscape Beyond Immunotherapy in Advanced Urothelial Carcinoma: Moving Past the Checkpoint.
Tripathi A; MacDougall K; Sonpavde GP
Drugs; 2022 Nov; 82(17):1649-1662. PubMed ID: 36441503
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
33. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
[TBL] [Abstract][Full Text] [Related]
35. Emerging therapeutic agents for genitourinary cancers.
Zarrabi K; Paroya A; Wu S
J Hematol Oncol; 2019 Sep; 12(1):89. PubMed ID: 31484560
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy: The Wave of the Future in Bladder Cancer?
Petrylak DP
Clin Genitourin Cancer; 2017 Jun; 15(3S):S3-S17. PubMed ID: 28633756
[TBL] [Abstract][Full Text] [Related]
37. Current State of Cell Therapies for Genitourinary Malignancies.
Alkhouli MA; Bazargan S; Pilon-Thomas S; Poch M; Chahoud J
Cancer J; 2022 Jul-Aug 01; 28(4):294-300. PubMed ID: 35880939
[TBL] [Abstract][Full Text] [Related]
38. Avelumab in locally advanced or metastatic urothelial carcinoma.
Jackson-Spence F; Szabados B; Toms C; Yang YH; Sng C; Powles T
Expert Rev Anticancer Ther; 2022 Feb; 22(2):135-140. PubMed ID: 35015593
[TBL] [Abstract][Full Text] [Related]
39. Novel immunotherapy combinations for genitourinary cancers.
Al Harthy M; Redman J; Madan RA
Expert Opin Biol Ther; 2020 Mar; 20(3):253-262. PubMed ID: 31914333
[TBL] [Abstract][Full Text] [Related]
40. Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer.
Lenfant L; Aminsharifi A; Seisen T; Rouprêt M
Curr Opin Urol; 2020 May; 30(3):428-440. PubMed ID: 32141936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
